Please select the option that best describes you:
How would you treat a post-menopausal woman with recurrent breast cancer, T1bN0 HR+ (ER/PR > 90%), HER2- s/p lumpectomy and adjuvant RT with low oncotype of 6?
Is deferring chemotherapy based on low oncotype acceptable in setting of recurrence?
Would you recommend using a different AI, Tamoxifen, or Fulvestrant as endocrine therapy if Exemestane was used for initial breast cancer 3 years ago?
Answer from: Medical Oncologist at Community Practice
In the CALOR trial that studied chemo vs. no chemo after resection of isolated locoregional recurrence, there is benefit of adjuvant chemotherapy. The 5-year HR for DFS with chemo was 0.59. The 5-year HR for OS with chemo was 0.41. The benefit was mainly seen in HR- patients. This patient has a very...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
The question does not provide the details of recurrence as to whether this is a locoregional breast recurrence, with or without lymph node or chest wall involvement. Ipsilateral or contralateral or second primary? Prior lumpectomy margins, prior type, and extent of radiation therapy? Time to recurre...